Anthony Simchak, MD
Neurology · Lafayette, INNPI 1639176530
Payments from drug & device makers
Across 1,802 payments — averaging $399.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$270K
- Neurocrine Biosciences, Inc.$209K
- Amgen$81K
- Lilly USA, LLC$44K
- Teva Pharmaceuticals USA, Inc.$32K
- Biohaven Pharmaceuticals, Inc.$20K
- plus $64K from 45 others
What the payments were for
- Consulting fees$51,1957%
- Speaking & faculty fees$600,97583%
- Grants$880%
- Travel & lodging$37,0755%
- Food & beverage$28,6984%
- Education$1,7510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$719,781 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 57 | $568,927 |
| IngrezzaValbenazine Tosylate | 35 | $280,682 |
| BotoxOnabotulinumtoxina | 140 | $222,392 |
| WakixPitolisant Hcl | 17 | $121,058 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $108,003 |
| Aimovig AutoinjectorErenumab-Aooe | 108 | $106,292 |
| Emgality PenGalcanezumab-Gnlm | 121 | $96,159 |
| UbrelvyUbrogepant | 58 | $85,899 |
| NuplazidPimavanserin Tartrate | 17 | $85,236 |
| QuliptaAtogepant | 70 | $78,820 |
| Teriflunomide | 20 | $70,213 |
| Nurtec OdtRimegepant Sulfate | 53 | $64,747 |
| GocovriAmantadine Hcl | 19 | $63,921 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $54,337 |
| BriviactBrivaracetam | 36 | $46,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta, Vraylar, Namzaric | $269,978 | $422,272293 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $209,474 | $299,33462 claims |
| Harmony Biosciences LLCWakix | $78 | $121,05817 claims |
| Acadia Pharmaceuticals IncNuplazid | $542 | $85,23617 claims |
| PfizerNurtec Odt | $1,787 | $64,74753 claims |
| MDD US Operations, LLCGocovri | $1,639 | $63,92119 claims |
| UCB, Inc.Briviact | $939 | $46,88336 claims |
| Amneal Pharmaceuticals LLCRytary | $4,888 | $34,97382 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $47 | $34,95723 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $887 | $14,88611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.
Other neurology in Lafayette
- Khaled HammoudLafayette$55K
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Ajay GuptaFort Wayne$2.5M
- Christopher WilsonAvon$2M
- Alexandru BarboiIndianapolis$1.9M
- William ConteMerrillville$1.7M
- James StevensFort Wayne$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.